+ Watch EXEL
on My Watchlist
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
I suppose a market cap under $400mm is an alleged bargain with the presumed diversified R&D pipeline that EXEL has, but ...1 - It has ripped through more than $100mm cash the past two quarters and net cash was about $86mm, or less than $1.00/sh at 3-31-10.2 - MF generally indulges in recommending companies coining cash. EXEL is years away from that. Share dilution is likely to be huge over the next 2-3 years unless major milestone payments are likely.3 - Tax-loss selling in this one will likely be rampant by both institutions into end of October and retail into year end.4 - Two big institutions are (maybe were) at least 9% holders. If either are sellers, it's going to be under continued selling pressure.It wouldn't surprise me if EXEL was selling near its 11/08 lows near $2 some time over the next 6 months.
doubt it buddy, things are on the up and up.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions